Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Christopher J. Schultz MD

Christopher J. Schultz MD

Chair, Professor

Institution: Medical College of Wisconsin
Department: Radiation Oncology
Program: Clinical

Member of the Cancer Center
Member of the Neuroscience Research Center
Member of the Genomic Sciences and Precision Medicine Center (GSPMC)


  • Phase 2 Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. (Lieberman FS, Wang M, Robins HI, Tsien CI, Curran WJ Jr, Werner-Wasik M, Smith RP, Schultz C, Hartford AC, Zhang P, Mehta MP) Int J Radiat Oncol Biol Phys 2018 Nov 26 PMID: 30496882 11/30/2018    
  • Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order. (Bovi JA, Schultz CJ, Mehta MP, Corn BW) Int J Radiat Oncol Biol Phys 2018 Sep 01;102(1):59-60 PMID: 30102204 08/14/2018    
  • Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. (Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A) JAMA Oncol 2018 Oct 01;4(10):1405-1409 PMID: 29955793 PMCID: PMC6117103 06/30/2018       2 Citations
  • Early Prediction of Acute Xerostomia During Radiation Therapy for Head and Neck Cancer Based on Texture Analysis of Daily CT. (Wu H, Chen X, Yang X, Tao Y, Xia Y, Deng X, Zheng C, Robbins J, Schultz C, Li XA) Int J Radiat Oncol Biol Phys 2018 Nov 15;102(4):1308-1318 PMID: 29891201 06/13/2018       1 Citations
  • Current Predictive Indices and Nomograms To Enable Personalization of Radiation Therapy for Patients With Secondary Malignant Neoplasms of the Central Nervous System: A Review. (Gilbride L, Siker M, Bovi J, Gore E, Schultz C, Hall WA) Neurosurgery 2018 May 01;82(5):595-603 PMID: 29669114 04/19/2018    
  • NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. (Ali AN, Zhang P, Yung WKA, Chen Y, Movsas B, Urtasun RC, Jones CU, Choi KN, Michalski JM, Fischbach AJ, Markoe AM, Schultz CJ, Penas-Prado M, Garg MK, Hartford AC, Kim HE, Won M, Curran WJ Jr) J Neurooncol 2018 Mar;137(1):39-47 PMID: 29404979 PMCID: PMC6020014 02/07/2018    
  • Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. (Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY) Int J Radiat Oncol Biol Phys 2018 Jun 01;101(2):274-284 PMID: 28964588 10/02/2017    
  • R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. (Verkooijen HM, Kerkmeijer LGW, Fuller CD, Huddart R, Faivre-Finn C, Verheij M, Mook S, Sahgal A, Hall E, Schultz C) Front Oncol 2017;7:59 PMID: 28421162 PMCID: PMC5378068 04/20/2017    
  • Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. (Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M) Neuro Oncol 2017 02 01;19(2):252-258 PMID: 27994066 PMCID: PMC5463834 12/21/2016       17 Citations
  • The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development. (Kerkmeijer LG, Fuller CD, Verkooijen HM, Verheij M, Choudhury A, Harrington KJ, Schultz C, Sahgal A, Frank SJ, Goldwein J, Brown KJ, Minsky BD, van Vulpen M, MR-Linac Consortium Clinical Steering Committee) Front Oncol 2016;6:215 PMID: 27790408 PMCID: PMC5061756 10/30/2016    
  • Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy in Head and Neck Squamous Cell Carcinoma: A Pooled Analysis of NRG Oncology/RTOG 0129 and 0522. (Yao M, Zhang Q, Woods CR, Nguyen-Tan PF, Rosenthal DI, Garden AS, Thorstad WL, Anne PR, Schultz CJ, Caudell JJ, Filion E, Ridge JA, Jones CU, Kim H, Yom SS, Raben D, Bonner JA, Machtay M, Harris J, Le QT) Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):S116-S117 PMID: 27675562 09/28/2016    
  • Pulsed Reduced Dose Rate Reirradiation (PRDR) Using Modulated Arc (mARC) Intensity Modulated Radiation Therapy for Recurrent Gliomas: Initial Clinical Outcomes of a Novel Technique. (Siker ML, Firat S, Prah D, Schultz CJ, Dayal A, Masterson C, Connelly JM, Mueller WM, Bovi JA) Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E125-E126 PMID: 27673841 09/28/2016    
  • Clinical Significance of Updated MRI Simulation Versus Immediate Postoperative MRI for Radiation Treatment Planning in Patients With Glioblastoma: Changes in FLAIR Signal. (Dayal A, Siker ML, Firat S, Bovi JA, Schultz CJ, Mueller WM, Connelly JM, Rand SD) Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E103 PMID: 27673785 09/28/2016    
  • A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813. (Bell EH, McElroy JP, Fleming J, Timmers C, Chakraborty AR, Salavaggione AL, Chang SM, Shaw EG, Aldape K, Brachman D, Schultz CJ, Shih HA, Curtis M, Hunter GK, Murtha AD, Zhang P, Won M, Mehta MP, Chakravarti A) Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):S91 PMID: 27676051 09/28/2016    
  • Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent chemotherapy and radiation therapy in high-risk squamous cell carcinoma of the head and neck. (b. Spencer SA, Harris J, Wheeler RH, Machtay M, SCHULTZ C, Spanos W, Rotman M, Meredith R, Ang KK ) N Engl J Med 350 (19): 1937-1944 08/08/2016    
  • Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. (b. Spencer SA, Harris J, Wheeler RH, Machtay M, SCHULTZ C, Spanos W, Rotman M, Meredith R, Ang KK) Head Neck Mar;30(3):281-8 08/08/2016    
  • Treatment of recurrent glioblastoma with Bevacizumba with or without re-irradiation using a pulsed-low-dose radietion therapy technique: A single institution experience. ( Bovi JA, Prah M, Rand SD, SCHULTZ CJ, Schmanda KM) Int J Radiat Oncol Biol Phys 90:S1, Abs #2179, S288 08/08/2016    
  • Development of an inverse optimization package to plan non-uniform dose distributions based on spatially inhomogeneous radiosensitivity extracted from biological images (Cheng GP, Ahunbay E, SCHULTZ C, Li XA) Med Phys 34(4)April 08/08/2016    
  • Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. (Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS) AJNR Am J Neuroradiol 2016 12;37(12):2201-2208 PMID: 27492073 PMCID: PMC5161572 08/06/2016       14 Citations
  • Technical Note: Dose effects of 1.5 T transverse magnetic field on tissue interfaces in MRI-guided radiotherapy. (Chen X, Prior P, Chen GP, Schultz CJ, Li XA) Med Phys 2016 Aug;43(8):4797 PMID: 27487897 08/05/2016       6 Citations
  • Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. (Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ Jr) N Engl J Med 2016 Apr 07;374(14):1344-55 PMID: 27050206 PMCID: PMC5170873 04/07/2016       228 Citations
  • Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. (Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP) J Clin Oncol 2016 05 10;34(14):1620-5 PMID: 27022122 PMCID: PMC4872318 03/30/2016       32 Citations
  • Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme. (Elson A, Paulson E, Bovi J, Siker M, Schultz C, Laviolette PS) J Neurooncol 2015 May;123(1):179-88 PMID: 25894597 04/22/2015       9 Citations
  • Computed tomography number changes observed during computed tomography-guided radiation therapy for head and neck cancer. (Feng M, Yang C, Chen X, Xu S, Moraru I, Lang J, Schultz C, Li XA) Int J Radiat Oncol Biol Phys 2015 Apr 01;91(5):1041-7 PMID: 25832695 04/04/2015       11 Citations
  • Use of Helical TomoTherapy for the Focal Hypofractionated Treatment of Limited Brain Metastases in the Initial and Recurrent Setting. (Elson A, Walker A, Bovi JA, Schultz C) Front Oncol 2015;5:27 PMID: 25709970 PMCID: PMC4321406 02/25/2015    
  • Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma. (Elson A, Bovi J, Siker M, Schultz C, Paulson E) J Neurooncol 2015 May;122(3):549-58 PMID: 25700835 02/24/2015       7 Citations
  • Comparing the quality of passively-scattered proton and photon tomotherapy plans for brain and head and neck disease sites. (Kainz K, Firat S, Wilson JF, Schultz C, Siker M, Wang A, Olson D, Li XA) Phys Med Biol 2015 Mar 21;60(6):2167-77 PMID: 25683607 02/17/2015    
  • Comprehensive MRI simulation methodology using a dedicated MRI scanner in radiation oncology for external beam radiation treatment planning. (Paulson ES, Erickson B, Schultz C, Allen Li X) Med Phys 2015 Jan;42(1):28-39 PMID: 25563245 01/08/2015       40 Citations
  • Effect of treatment modality on the hypothalamic-pituitary function of patients treated with radiation therapy for pituitary adenomas: hypothalamic dose and endocrine outcomes. (Elson A, Bovi J, Kaur K, Maas D, Sinson G, Schultz C) Front Oncol 2014;4:73 PMID: 24782984 PMCID: PMC3988389 05/02/2014    
  • Combined online and offline adaptive radiation therapy: a dosimetric feasibility study. (Yang C, Liu F, Ahunbay E, Chang YW, Lawton C, Schultz C, Wang D, Firat S, Erickson B, Li XA) Pract Radiat Oncol 2014 Jan-Feb;4(1):e75-83 PMID: 24621436 03/14/2014       8 Citations
  • Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). (Krauze AV, Won M, Graves C, Corn BW, Muanza TM, Howard SP, Mahadevan A, Schultz CJ, Haas ML, Mehta MP, Camphausen KA) Biomark Res 2013 Oct 31;1(1):29 PMID: 24252135 PMCID: PMC4177620 11/21/2013    
  • Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. (Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP) J Clin Oncol 2013 Nov 10;31(32):4085-91 PMID: 24101040 PMCID: PMC3816958 10/09/2013       334 Citations
  • The role of pre-treatment white matter abnormalities in developing white matter changes following whole brain radiation: a volumetric study. (Sabsevitz DS, Bovi JA, Leo PD, Laviolette PS, Rand SD, Mueller WM, Schultz CJ) J Neurooncol 2013 Sep;114(3):291-7 PMID: 23813291 07/03/2013       2 Citations
  • American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS). (Seung SK, Larson DA, Galvin JM, Mehta MP, Potters L, Schultz CJ, Yajnik SV, Hartford AC, Rosenthal SA) Am J Clin Oncol 2013 Jun;36(3):310-5 PMID: 23681017 PMCID: PMC4285440 05/18/2013       29 Citations
  • RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. (Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M) Int J Radiat Oncol Biol Phys 2013 Apr 01;85(5):1206-11 PMID: 23182702 PMCID: PMC4199329 11/28/2012       58 Citations
  • American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for Intensity-modulated Radiation Therapy (IMRT). (Hartford AC, Galvin JM, Beyer DC, Eichler TJ, Ibbott GS, Kavanagh B, Schultz CJ, Rosenthal SA, American College of Radiology, American Society for Radiation Oncology) Am J Clin Oncol 2012 Dec;35(6):612-7 PMID: 23165357 11/21/2012       32 Citations
  • Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. (Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK) Int J Radiat Oncol Biol Phys 2012 Dec 01;84(5):1198-205 PMID: 22749632 PMCID: PMC3465463 07/04/2012       167 Citations
  • Elective lymph node irradiation with intensity-modulated radiotherapy: is conventional dose fractionation necessary? (Bedi M, Firat S, Semenenko VA, Schultz C, Tripp P, Byhardt R, Wang D) Int J Radiat Oncol Biol Phys 2012 May 01;83(1):e87-92 PMID: 22516389 04/21/2012       10 Citations
  • Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck. (Kharofa J, Choong N, Wang D, Firat S, Schultz C, Sadasiwan C, Wong S) Int J Radiat Oncol Biol Phys 2012 Jun 01;83(2):690-5 PMID: 22112556 11/25/2011       15 Citations
  • Internal margin assessment using cine MRI analysis of deglutition in head and neck cancer radiotherapy. (Paulson ES, Bradley JA, Wang D, Ahunbay EE, Schultz C, Li XA) Med Phys 2011 Apr;38(4):1740-7 PMID: 21626908 06/02/2011       9 Citations
  • Prognostic value of H-MLH1 after adjusting for RPA class in GBM patients. (Choucair A, Moughan J, Schultz C, Schulsinger A, Mehta M, Curran W) Front Biosci (Elite Ed) 2011 Jun 01;3:1182-91 PMID: 21622124 05/31/2011       1 Citations
  • Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial. (McHaffie DR, Chabot P, Dagnault A, Suh JH, Fortin MA, Chang E, Timmerman R, Souhami L, Grecula J, Nabid A, Schultz C, Werner-Wasik M, Gaspar LE, Brachman D, Mody T, Mehta MP) J Neurooncol 2011 Nov;105(2):301-8 PMID: 21523486 04/28/2011       12 Citations
  • Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer. (Zundel MT, Michel MA, Schultz CJ, Maheshwari M, Wong SJ, Campbell BH, Massey BL, Blumin J, Wilson JF, Wang D) Int J Radiat Oncol Biol Phys 2011 Dec 01;81(5):e825-32 PMID: 21300450 02/09/2011       32 Citations
  • Dynamic MRI analysis of tumor and organ motion during rest and deglutition and margin assessment for radiotherapy of head-and-neck cancer. (Bradley JA, Paulson ES, Ahunbay E, Schultz C, Li XA, Wang D) Int J Radiat Oncol Biol Phys 2011 Dec 01;81(5):e803-12 PMID: 21300480 02/09/2011       18 Citations
  • Semicontinuous low-dose-rate teletherapy for the treatment of recurrent glial brain tumors: final report of a phase I/II study. (Siker ML, Firat SY, Mueller W, Krouwer H, Schultz CJ) Int J Radiat Oncol Biol Phys 2012 Feb 01;82(2):765-72 PMID: 21236600 01/18/2011       4 Citations
  • Current management of primary central nervous system lymphoma. (Schultz CJ, Bovi J) Int J Radiat Oncol Biol Phys 2010 Mar 01;76(3):666-78 PMID: 20159361 02/18/2010       32 Citations
  • Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. (Parker SM, Olteanu H, VanTuinen P, Lawton CA, Schultz CJ, Christians KK, Fenske TS) Int J Hematol 2009 Dec;90(5):616-622 PMID: 19937165 11/26/2009       9 Citations
  • An on-line replanning method for head and neck adaptive radiotherapy. (Ahunbay EE, Peng C, Godley A, Schultz C, Li XA) Med Phys 2009 Oct;36(10):4776-90 PMID: 19928108 11/26/2009       37 Citations
  • Role of radiation therapy in cutaneous melanoma. (Shuff JH, Siker ML, Daly MD, Schultz CJ) Clin Plast Surg 2010 Jan;37(1):147-60 PMID: 19914465 11/17/2009       5 Citations
  • Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. (Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK) J Clin Oncol 2009 Oct 01;27(28):4727-32 PMID: 19720915 PMCID: PMC2754914 09/02/2009       26 Citations
  • American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). (Hartford AC, Palisca MG, Eichler TJ, Beyer DC, Devineni VR, Ibbott GS, Kavanagh B, Kent JS, Rosenthal SA, Schultz CJ, Tripuraneni P, Gaspar LE, American Society for Therapeutic Radiology and Oncology, American College of Radiology) Int J Radiat Oncol Biol Phys 2009 Jan 01;73(1):9-14 PMID: 19100920 12/23/2008       62 Citations
  • Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. (Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M) Neuro Oncol 2009 Apr;11(2):167-75 PMID: 18779504 PMCID: PMC2718988 09/10/2008       52 Citations
  • Synergistic effect of 15-lipoxygenase 2 and radiation in killing head-and-neck cancer. (Yang Q, Feng Y, Schultz CJ, Li XA, Wu H, Wang D) Cancer Gene Ther 2008 May;15(5):323-30 PMID: 18292796 02/23/2008       6 Citations
  • Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. (Vernon MR, Maheshwari M, Schultz CJ, Michel MA, Wong SJ, Campbell BH, Massey BL, Wilson JF, Wang D) Int J Radiat Oncol Biol Phys 2008 Mar 01;70(3):678-84 PMID: 18262086 02/12/2008       74 Citations
  • Possible fractionated regimens for image-guided intensity-modulated radiation therapy of large arteriovenous malformations. (Qi XS, Schultz CJ, Li XA) Phys Med Biol 2007 Sep 21;52(18):5667-82 PMID: 17804888 09/07/2007       17 Citations
  • Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. (Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, Rotman M, Meredith R, Ang KK) Head Neck 2008 Mar;30(3):281-8 PMID: 17764087 09/04/2007       155 Citations
  • Development of an inverse optimization package to plan nonuniform dose distributions based on spatially inhomogeneous radiosensitivity extracted from biological images. (Chen GP, Ahunbay E, Schultz C, Li XA) Med Phys 2007 Apr;34(4):1198-205 PMID: 17500451 05/16/2007       17 Citations
  • Interfractional variations in patient setup and anatomic change assessed by daily computed tomography. (Li XA, Qi XS, Pitterle M, Kalakota K, Mueller K, Erickson BA, Wang D, Schultz CJ, Firat SY, Wilson JF) Int J Radiat Oncol Biol Phys 2007 Jun 01;68(2):581-91 PMID: 17331669 03/03/2007       83 Citations
  • Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. (Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP, Yung WK, Radiation Therapy Oncology Group) Int J Radiat Oncol Biol Phys 2006 Nov 01;66(3):818-24 PMID: 16887285 08/05/2006       32 Citations
  • Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. (Wang D, Schultz CJ, Jursinic PA, Bialkowski M, Zhu XR, Brown WD, Rand SD, Michel MA, Campbell BH, Wong S, Li XA, Wilson JF) Int J Radiat Oncol Biol Phys 2006 May 01;65(1):143-51 PMID: 16618577 04/19/2006       111 Citations
  • An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor. (Qi XS, Schultz CJ, Li XA) Int J Radiat Oncol Biol Phys 2006 Apr 01;64(5):1570-80 PMID: 16580506 04/04/2006       21 Citations
  • Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. (Robins HI, Won M, Seiferheld WF, Schultz CJ, Choucair AK, Brachman DG, Demas WF, Mehta MP) Neuro Oncol 2006 Jan;8(1):47-52 PMID: 16443947 PMCID: PMC1871929 01/31/2006       42 Citations
  • Effect of image uncertainty on the dosimetry of trigeminal neuralgia irradiation. (Jursinic PA, Rickert K, Gennarelli TA, Schultz CJ) Int J Radiat Oncol Biol Phys 2005 Aug 01;62(5):1559-67 PMID: 16029818 07/21/2005       12 Citations
  • Planning quality and delivery efficiency of sMLC delivered IMRT treatment of oropharyngeal cancers evaluated by RTOG H-0022 dosimetric criteria. (Zhu XR, Schultz CJ, Gillin MT) J Appl Clin Med Phys 2004;5(4):80-95 PMID: 15738923 PMCID: PMC5723523 03/02/2005       6 Citations
  • Late-onset chemosis in patients with head or neck tumors. (Harris GJ, Woo KI, Schultz CJ, Tayani R, Cancel EM) Ophthalmic Plast Reconstr Surg 2004 Nov;20(6):436-41 PMID: 15599243 12/16/2004       3 Citations
  • Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. (Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ Jr) Int J Radiat Oncol Biol Phys 2004 Nov 01;60(3):853-60 PMID: 15465203 10/07/2004       348 Citations
  • Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. (Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK, Radiation Therapy Oncology Group 9501/Intergroup) N Engl J Med 2004 May 06;350(19):1937-44 PMID: 15128893 05/07/2004       1687 Citations
  • Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. (Chang CC, Kampalath B, Schultz C, Bunyi-Teopengco E, Logan B, Eshoa C, Dincer AP, Perkins SL) Arch Pathol Lab Med 2003 Feb;127(2):208-12 PMID: 12562237 02/04/2003       59 Citations
  • A new magnetic resonance head coil and head immobilization device for gamma knife radiosurgery: an analysis of geometric distortion and signal/noise characteristics. (Jursinic P, Prost R, Schultz C) J Neurosurg 2002 Dec;97(5 Suppl):563-8 PMID: 12507097 01/01/2003       9 Citations
  • Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. (DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ, Radiation Therapy Oncology Group Study 93-10) J Clin Oncol 2002 Dec 15;20(24):4643-8 PMID: 12488408 12/19/2002       473 Citations
  • Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. (Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF) J Clin Oncol 2002 Aug 15;20(16):3445-53 PMID: 12177105 08/15/2002       121 Citations
  • Radiation Therapy Oncology Group. Research Plan 2002-2006. Image-Guided Radiation Therapy Committee. (Michalski J, Purdy JA, Gaspar L, Souhami L, Ballow M, Bradley J, Chao CK, Crane C, Eisbruch A, Fallowil D, Forster K, Fowler J, Gillin MT, Graham ML, Harms WB, Huq MS, Kline RW, Mackie TR, Mukherji S, Podogorsak EB, Roach M, Ryu J, Sandler H, Schultz CJ, Schell M, Verhey LJ, Vicini F, Winter KA, Radiation Therapy Oncology Group) Int J Radiat Oncol Biol Phys 2001;51(3 Suppl 2):60-5 PMID: 11641018 10/20/2001       13 Citations
  • Planned postradiotherapy neck dissection in patients with advanced head and neck cancer. (Boyd TS, Harari PM, Tannehill SP, Voytovich MC, Hartig GK, Ford CN, Foote RL, Campbell BH, Schultz CJ) Head Neck 1998 Mar;20(2):132-7 PMID: 9484944 03/04/1998       90 Citations
  • The role of dental prostheses in alveolar ridge squamous carcinomas. (Campbell BH, Mark DH, Soneson EA, Freije JE, Schultz CJ) Arch Otolaryngol Head Neck Surg 1997 Oct;123(10):1112-5 PMID: 9339989 10/27/1997       6 Citations
  • Carcinoma of the larynx in patients with gastroesophageal reflux. (Freije JE, Beatty TW, Campbell BH, Woodson BT, Schultz CJ, Toohill RJ) Am J Otolaryngol 1996 Nov-Dec;17(6):386-90 PMID: 8944297 11/01/1996       98 Citations
  • Demonstration of a brachytherapy boost dose-response relationship in glioblastoma multiforme: headed in the right direction. (Schultz CJ) Int J Radiat Oncol Biol Phys 1996 Apr 01;35(1):187-8 PMID: 8641918 04/01/1996    
  • A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. (Auchter RM, Lamond JP, Alexander E, Buatti JM, Chappell R, Friedman WA, Kinsella TJ, Levin AB, Noyes WR, Schultz CJ, Loeffler JS, Mehta MP) Int J Radiat Oncol Biol Phys 1996 Apr 01;35(1):27-35 PMID: 8641923 04/01/1996       412 Citations
  • Stage I and II Hodgkin's disease in the pediatric population. Long-term follow-up of patients staged predominantly clinically. (Rock DB, Murray KJ, Schultz CJ, Lauer SJ, Wilson JF) Am J Clin Oncol 1996 Apr;19(2):174-8 PMID: 8610644 04/01/1996       5 Citations
  • Lymphoepithelioma of the larynx. (Andryk J, Freije JE, Schultz CJ, Campbell BH, Komorowski RA) Am J Otolaryngol 1996 Jan-Feb;17(1):61-3 PMID: 8801819 01/01/1996       15 Citations
  • Risk factors which predict persistent cancer in the abnormal larynx following definitive irradiation. (Schultz CJ, Campbell BH, Freije JE, Brook BJ, McAuliffe TL) Eur J Cancer B Oral Oncol 1995 Sep;31B(5):310-4 PMID: 8704647 09/01/1995       8 Citations
  • Iododeoxyuridine radiosensitization of human glioblastoma cells exposed to acute and chronic gamma irradiation: mechanistic implications and clinical relevance. (Schultz CJ, Gaffney DK, Lindstrom MJ, Kinsella TJ) Cancer J Sci Am 1995 Jul-Aug;1(2):151-61 PMID: 9166468 07/01/1995       13 Citations
  • Continuous split course irradiation for stage I and II Hodgkin's disease: 20 year experience at the Medical College of Wisconsin. (Rock DB, Schultz CJ, Murray KJ, Wilson JF, Cox JD) Radiother Oncol 1994 Mar;30(3):222-6 PMID: 8209005 03/01/1994       6 Citations
  • Central lymphatic irradiation for stage III nodular malignant lymphoma: long-term results. (Jacobs JP, Murray KJ, Schultz CJ, Wilson JF, Goswitz MS, Stevens CW, Cox JD) J Clin Oncol 1993 Feb;11(2):233-8 PMID: 8426199 02/01/1993       61 Citations
  • Radioresponse of human astrocytic tumors across grade as a function of acute and chronic irradiation. (Schultz CJ, Geard CR) Int J Radiat Oncol Biol Phys 1990 Dec;19(6):1397-403 PMID: 2262364 12/01/1990       53 Citations
  • Chloroquine poisoning in a child. (Kelly JC, Wasserman GS, Bernard WD, Schultz C, Knapp J) Ann Emerg Med 1990 Jan;19(1):47-50 PMID: 2297155 01/01/1990       24 Citations
  • Last update: 12/03/2018
    jenkins-FCD Prod-299 9ef562391eceb2b8f95265c767fbba1ce5a52fd6